Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Bactiguard Holding AB (publ)
  6. News
  7. Summary
    BACTI B   SE0005878741

BACTIGUARD HOLDING AB (PUBL)

(BACTI B)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 12/03 11:29:58 am
151.8 SEK   -2.69%
11/18BACTIGUARD : Stop antimicrobial resistance through awareness
PU
11/17BACTIGUARD : ranks higher on Allbright's list of equality
PU
11/16CEO Anders Göransson invests in Bactiguard
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bactiguard : New clinical trial shows 53% reduction of ventilator-associated pneumonia with Bactiguard's endotracheal tube

10/05/2021 | 02:01am EST

This week at the European Society of Intensive Care congress (ESICM), a study from Liège, Belgium on Bactiguard's endotracheal tubes was presented. The study showed a 53% reduction in ventilator-associated pneumonia (VAP) in intensive care patients, intubated with Bactiguard's endotracheal tube with evacuation lumen (BIP ETT Evac).

"These data are of vital importance for critically ill patients across the world. Ventilator-associated pneumonia (VAP) is a feared complication with high mortality. The study data indicates that by using a Bactiguard endotracheal tube the risk of this deadly complication is significantly reduced", says Stefan Grass, Chief Medical Officer and Deputy CEO.

The study is a randomized-controlled study including 323 patients, either intubated with a Bactiguard endotracheal tube or a conventional tube (both with subglottic suctioning port). The number of VAP cases were 22.4 per 1000 ventilator days in the control group compared with 10.5 in the Bactiguard group which was just short of significance (p=0.07). The time to occurrence of VAP was significantly reduced in the Bactiguard group (p=0.02).

"During the COVID-19 pandemic there are multiple reports showing increased VAP rates in ICU patients and the use of our products can contribute to reducing these numbers. Actually, the study is called VITAL and the results proved to be just that", Stefan Grass concludes.

The VITAL study was selected as top 6 best abstracts at the ESICM congress. For registered ESICM delegates the poster can be found in the event platform: https://lives2021.e-lives.org/. Prof Misset is the presenter of the study.

About BIP Endotracheal Tube Evac

Bactiguard's BIP ETT Evac is the only tube on the market that combines the subglottic secretion drainage with the clinically proven ability of the Bactiguard technology to reduce microbial adhesion The technology is based on a very thin noble metal alloy coating, firmly attached to the tube surface. When in contact with fluids, the noble metals create a galvanic effect which reduces microbial adhesion. This means that less bacteria adhere to the tube surface, which reduces the risk of biofilm formation leading to infection.

For more information, please contact:
Stefan Grass, Chief Medical Officer and Deputy CEO, mobile +46 70 725 24 48
 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com

https://news.cision.com/bactiguard-holding-ab--publ-/r/new-clinical-trial-shows-53--reduction-of-ventilator-associated-pneumonia-with-bactiguard-s-endotrac,c3427044

https://mb.cision.com/Main/9686/3427044/1477031.pdf

https://news.cision.com/bactiguard-holding-ab--publ-/i/bactiguard-bip-ett-evac,c2963668

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about BACTIGUARD HOLDING AB (PUBL)
11/18BACTIGUARD : Stop antimicrobial resistance through awareness
PU
11/17BACTIGUARD : ranks higher on Allbright's list of equality
PU
11/16CEO Anders Göransson invests in Bactiguard
AQ
10/29Nomination Committee appointed for the Annual General Meeting 2022
AQ
10/29Bactiguard Holding AB Appoints Nomination Committee
CI
10/28Interim report for Q3 2021
AQ
10/28Bactiguard Holding AB Reports Earnings Results for the Third Quarter and Nine Months En..
CI
10/25BACTIGUARD : Invitation to presentation of Bactiguard's interim report on October 28, 2021
PU
10/25BACTIGUARD : Invitation to presentation of Bactiguard's interim report on October 28, 2021
AQ
10/08BACTIGUARD : More than 50% risk reduction of ventilator associated pneumonia with Bactigua..
PU
More news
Financials
Sales 2020 177 M 19,4 M 19,4 M
Net income 2020 -38,4 M -4,21 M -4,21 M
Net Debt 2020 254 M 27,9 M 27,9 M
P/E ratio 2020 -125x
Yield 2020 -
Capitalization 5 320 M 581 M 583 M
EV / Sales 2019 15,5x
EV / Sales 2020 28,6x
Nbr of Employees -
Free-Float 36,4%
Chart BACTIGUARD HOLDING AB (PUBL)
Duration : Period :
Bactiguard Holding AB (publ) Technical Analysis Chart | BACTI B | SE0005878741 | MarketScreener
Technical analysis trends BACTIGUARD HOLDING AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Anders G÷ransson Chief Executive Officer
Gabriella Bj÷rknert Caracciolo Chief Financial Officer & Deputy CEO
Nils Thomas von Koch Chairman
Stefan Grass Chief Medical Officer & Deputy CEO
Sathish Subramaniam Chief Operations Officer